FBN3

Summary

FBN3 (fibrillin 3, HGNC:18794) is a protein-coding gene on chromosome 19p13.2, encoding Fibrillin-3 (Q75N90). Fibrillins are structural components of 10-12 nm extracellular calcium-binding microfibrils, which occur either in association with elastin or in elastin-free bundles.

This gene encodes a memebr of the fibrillin protein family. Fibrillins are extracellular matrix molecules that assemble into microfibrils in many connective tissues. This gene is most highly expressed in fetal tissues and its protein product is localized to extracellular microfibrils of developing skeletal elements, skin, lung, kidney, and skeletal muscle. This gene is potentially involved in Weill-Marchesani syndrome.

Source: NCBI Gene 84467 — RefSeq curated summary.

At a glance

• GWAS associations: 11
• Clinical variants (ClinVar): 1,691 total
• MANE Select transcript: NM_032447

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:18794
Approved symbol	FBN3
Name	fibrillin 3
Location	19p13.2
Locus type	gene with protein product
Status	Approved
Aliases	KIAA1776
Ensembl gene	ENSG00000142449
Ensembl biotype	protein_coding
OMIM	608529
Entrez	84467

Gene structure

Transcript identifiers

Ensembl transcripts: 11 — 8 protein_coding, 3 retained_intron

ENST00000270509, ENST00000594331, ENST00000595036, ENST00000598269, ENST00000600128, ENST00000601281, ENST00000601739, ENST00000602121, ENST00000651877, ENST00000924671, ENST00000924672

RefSeq mRNA: 2 — MANE Select: NM_032447 NM_001321431, NM_032447

CCDS: CCDS12196

Canonical transcript exons

ENST00000600128 — 64 exons

Exon	Start	End
ENSE00001154879	8083247	8083372
ENSE00001154898	8086200	8086325
ENSE00001273064	8072048	8072198
ENSE00001273072	8073063	8073297
ENSE00001273078	8075071	8075190
ENSE00001273087	8075283	8075411
ENSE00001273094	8081003	8081119
ENSE00001273103	8081358	8081480
ENSE00001273116	8085363	8085569
ENSE00001273134	8087077	8087211
ENSE00001273173	8089894	8089959
ENSE00001599701	8145843	8145938
ENSE00001604615	8131554	8131829
ENSE00001606436	8108170	8108238
ENSE00001612369	8109631	8109753
ENSE00001614229	8123784	8124008
ENSE00001619216	8135961	8136086
ENSE00001623407	8096444	8096569
ENSE00001625511	8117464	8117589
ENSE00001625968	8097289	8097414
ENSE00001631744	8146127	8146225
ENSE00001633301	8096881	8097006
ENSE00001634023	8126713	8126832
ENSE00001634540	8111977	8112099
ENSE00001635662	8115515	8115640
ENSE00001639955	8121258	8121386
ENSE00001648959	8102724	8102873
ENSE00001649604	8118897	8119022
ENSE00001658867	8091465	8091590
ENSE00001663237	8095375	8095503
ENSE00001674064	8094446	8094565
ENSE00001678797	8125892	8126017
ENSE00001700653	8144877	8144972
ENSE00001711653	8116674	8116799
ENSE00001713592	8132984	8133106
ENSE00001716869	8123464	8123589
ENSE00001722416	8129028	8129153
ENSE00001726109	8117169	8117291
ENSE00001728923	8100901	8100972
ENSE00001734041	8138412	8138564
ENSE00001735594	8106108	8106233
ENSE00001737736	8126468	8126605
ENSE00001742920	8110845	8110967
ENSE00001743873	8126297	8126347
ENSE00001751018	8109227	8109388
ENSE00001752225	8141940	8142137
ENSE00001753717	8090099	8090251
ENSE00001760361	8141717	8141842
ENSE00001763913	8138141	8138323
ENSE00001766499	8103562	8103687
ENSE00001777763	8136190	8136309
ENSE00001780766	8095964	8096080
ENSE00001787967	8136388	8136531
ENSE00001790671	8111648	8111770
ENSE00001791395	8129240	8129365
ENSE00001797648	8147104	8147186
ENSE00001802000	8131235	8131288
ENSE00003075325	8149449	8149592
ENSE00003099017	8065402	8066260
ENSE00003116328	8147314	8147497
ENSE00003507119	8089545	8089670
ENSE00003545327	8087825	8087947
ENSE00003651061	8111058	8111183
ENSE00003684208	8088060	8088179

Expression profiles

Bgee: expression breadth ubiquitous, 131 present calls, max score 94.50.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.4336 / max 19.5608, expressed in 158 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
178930	0.2614	131
178931	0.1722	94

Top tissues by expression

243 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cortical plate	UBERON:0005343	94.50	gold quality
embryo	UBERON:0000922	88.48	gold quality
ganglionic eminence	UBERON:0004023	88.48	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	79.83	gold quality
ventricular zone	UBERON:0003053	79.54	gold quality
upper arm skin	UBERON:0004263	74.93	gold quality
secondary oocyte	CL:0000655	74.14	silver quality
vena cava	UBERON:0004087	73.98	silver quality
myocardium	UBERON:0002349	73.94	gold quality
nasal cavity epithelium	UBERON:0005384	72.80	gold quality
cerebellar vermis	UBERON:0004720	71.83	gold quality
kidney epithelium	UBERON:0004819	71.66	gold quality
parotid gland	UBERON:0001831	70.35	gold quality
metanephros	UBERON:0000081	69.76	gold quality
saliva-secreting gland	UBERON:0001044	69.70	gold quality
metanephros cortex	UBERON:0010533	69.39	gold quality
minor salivary gland	UBERON:0001830	69.36	gold quality
mouth mucosa	UBERON:0003729	68.76	gold quality
cortex of kidney	UBERON:0001225	67.94	gold quality
pons	UBERON:0000988	67.84	gold quality
body of tongue	UBERON:0011876	67.68	gold quality
buccal mucosa cell	CL:0002336	67.48	gold quality
left lobe of thyroid gland	UBERON:0001120	67.34	gold quality
cartilage tissue	UBERON:0002418	67.29	gold quality
thyroid gland	UBERON:0002046	67.26	gold quality
gingival epithelium	UBERON:0001949	67.22	gold quality
heart right ventricle	UBERON:0002080	66.97	gold quality
inferior vagus X ganglion	UBERON:0005363	66.87	gold quality
pylorus	UBERON:0001166	66.85	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	66.85	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.54

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

15 targeting FBN3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-515-5P	99.92	69.82	2343
HSA-MIR-519E-5P	99.92	69.62	2358
HSA-MIR-548E-5P	99.89	72.73	4486
HSA-MIR-1200	99.71	70.42	1838
HSA-MIR-377-5P	99.70	65.28	712
HSA-MIR-6086	99.70	65.38	699
HSA-MIR-378A-5P	99.65	66.33	1311
HSA-MIR-7109-5P	99.18	66.13	1057
HSA-MIR-328-5P	99.08	64.65	1000
HSA-MIR-143-5P	98.98	68.87	946
HSA-MIR-6885-5P	98.71	64.33	902
HSA-MIR-4700-5P	98.63	67.43	1915
HSA-MIR-6887-5P	98.56	68.49	1295
HSA-MIR-6795-5P	98.52	68.51	1277
HSA-MIR-4435	95.90	65.47	1201

Literature-anchored findings (GeneRIF, showing 11)

• fibrillin-3 gene showed the strongest evidence for association with Polycystic ovary syndrome (PMID:17785364)
• Data show that fibrillin 3 appears to have little involvement in PCOS but cannot rule out that other markers in the region of chromosome 19p13.2 are associated with PCOS or that FBN3 expression occurs in other organs that may influence the PCOS phenotype. (PMID:19692420)
• Single nucleotide polymorphisms in FBN3 occur and may be a candidate gene for polycystic ovary syndrome. (PMID:20200332)
• A variant in the fibrillin-3 gene is associated with TGF-beta and inhibin B levels in women with polycystic ovary syndrome. (PMID:20630504)
• Loss of fibrillin-3 during folliculogenesis may be an important factor in polycystic ovary syndrome pathogenesis. (PMID:20855553)
• fibrillin-3, compared to the other fibrillins, fulfills both overlapping and distinct functions in human development (PMID:20970500)
• Data show that TGF-beta pathways operate during ovarian fetal development, and fibrillin 3 is highly expressed at a critical stage early in developing human and bovine fetal ovaries. (PMID:21411746)
• The FBN3 risk allele may be associated with changes in basal glucose homeostasis in PCOS. (PMID:22301903)
• an association study showed a potential association of the D19S884 marker with PCOS in Chinese Han women and the meta-analysis identified that the A8 allele may increase susceptibility to PCOS (PMID:23265956)
• Further delineation of familial polycystic ovary syndrome (PCOS) via whole-exome sequencing: PCOS-related rare FBN3 and FN1 gene variants are identified. (PMID:35141985)
• Genetic Insights into Skeletal Malocclusion: The Role of the FBN3 rs7351083 SNP in the Romanian Population. (PMID:39064490)

Cross-species orthologs

1 orthologs

Organism	Symbol	Gene ID
danio_rerio	fbn2b	ENSDARG00000098237

Paralogs (2): FBN2 (ENSG00000138829), FBN1 (ENSG00000166147)

Protein

Protein identifiers

Fibrillin-3 — Q75N90 (reviewed: Q75N90)

All UniProt accessions (4): Q75N90, A0A494C0D8, M0QXL8, M0R2Q5

UniProt curated annotations — full annotation on UniProt →

Function. Fibrillins are structural components of 10-12 nm extracellular calcium-binding microfibrils, which occur either in association with elastin or in elastin-free bundles. Fibrillin-containing microfibrils provide long-term force bearing structural support.

Subcellular location. Secreted. Extracellular space. Extracellular matrix.

Tissue specificity. Predominantly expressed in connective tissues such as skeletal muscle, tendon, skin, perichondrium and periosteum. Highly expressed in fetal lung, brain, kidney. Expressed at low level in prostate, testis, mammary gland, uterus, ovary, placenta, bladder, adrenal gland, thyroid, fetal thymus, fetal liver, liver, fetal heart and heart.

Post-translational modifications. Probably forms intermolecular disulfide bonds either with other FBN3 molecules or with other components of the microfibrils.

Similarity. Belongs to the fibrillin family.

RefSeq proteins (2): NP_001308360, NP_115823* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000152	EGF-type_Asp/Asn_hydroxyl_site	PTM
IPR000742	EGF	Domain
IPR001881	EGF-like_Ca-bd_dom	Domain
IPR009030	Growth_fac_rcpt_cys_sf	Homologous_superfamily
IPR013032	EGF-like_CS	Conserved_site
IPR017878	TB_dom	Domain
IPR018097	EGF_Ca-bd_CS	Conserved_site
IPR024731	NELL2-like_EGF	Domain
IPR026823	cEGF	Domain
IPR036773	TB_dom_sf	Homologous_superfamily
IPR040872	Fibrillin_U_N	Domain
IPR049388	FBN_EGF_N	Domain
IPR049883	NOTCH1_EGF-like	Domain
IPR052080	vWF_C/EGF_Fibrillin	Family

Pfam: PF00683, PF07645, PF12661, PF12662, PF12947, PF18193, PF21364

UniProt features (229 total): disulfide bond 132, domain 53, sequence variant 30, glycosylation site 10, chain 2, signal peptide 1, propeptide 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

No AlphaFold model available for Q75N90 — AlphaFold DB does not currently provide models for proteins above ~3000 aa.

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (132): 990–1002, 997–1011, 1013–1026, 1032–1044, 1039–1053, 1055–1069, 1075–1087, 1082–1096, 1098–1111, 1117–1129, 1124–1138, 1140–1153, 1159–1170, 1166–1179, 1181–1194, 1200–1212, 1207–1221, 1223–1236, 1242–1254, 1249–1263 …

Glycosylation sites (10): 406, 1025, 1442, 1538, 1627, 1658, 1668, 1858, 2033, 2713

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-1474228	Degradation of the extracellular matrix
R-HSA-1566948	Elastic fibre formation
R-HSA-2129379	Molecules associated with elastic fibres

MSigDB gene sets: 77 (showing top): MODULE_511, GOBP_ANIMAL_ORGAN_MORPHOGENESIS, GOBP_EMBRYONIC_ORGAN_MORPHOGENESIS, GOMF_EXTRACELLULAR_MATRIX_STRUCTURAL_CONSTITUENT, GOBP_CARBOHYDRATE_METABOLIC_PROCESS, GOBP_GLUCOSE_METABOLIC_PROCESS, GOBP_CARBOHYDRATE_HOMEOSTASIS, MODULE_544, DOUGLAS_BMI1_TARGETS_UP, GOBP_EMBRYO_DEVELOPMENT, GOBP_EMBRYONIC_EYE_MORPHOGENESIS, GOBP_SENSORY_ORGAN_DEVELOPMENT, GOBP_SENSORY_ORGAN_MORPHOGENESIS, GOBP_MONOSACCHARIDE_METABOLIC_PROCESS, GOMF_SIGNALING_RECEPTOR_BINDING

GO Biological Process (5): glucose metabolic process (GO:0006006), glucose homeostasis (GO:0042593), camera-type eye development (GO:0043010), embryonic eye morphogenesis (GO:0048048), signal transduction (GO:0007165)

GO Molecular Function (4): hormone activity (GO:0005179), extracellular matrix structural constituent (GO:0005201), calcium ion binding (GO:0005509), extracellular matrix constituent conferring elasticity (GO:0030023)

GO Cellular Component (3): microfibril (GO:0001527), extracellular region (GO:0005576), extracellular matrix (GO:0031012)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Extracellular matrix organization	2
Elastic fibre formation	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
hexose metabolic process	1
carbohydrate homeostasis	1
eye development	1
embryonic organ morphogenesis	1
eye morphogenesis	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
receptor ligand activity	1
structural molecule activity	1
extracellular matrix	1
metal ion binding	1
extracellular matrix structural constituent	1
structural molecule activity conferring elasticity	1
elastic fiber	1
supramolecular fiber	1
cellular anatomical structure	1
external encapsulating structure	1

Protein interactions and networks

STRING

1575 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
FBN3	CCL25	O15444	698
FBN3	CAPN10	Q9HC96	690
FBN3	SRD5A1	P18405	672
FBN3	SULT2A1	Q06520	649
FBN3	DENND1A	Q8TEH3	624
FBN3	INSR	P06213	596
FBN3	H6PD	O95479	582
FBN3	SRD5A2	P31213	573
FBN3	KRR1	Q13601	571
FBN3	FST	P19883	570
FBN3	CYP11A1	P05108	547
FBN3	CYP17A1	P05093	538
FBN3	SUOX	P51687	525
FBN3	BBS10	Q8TAM1	523
FBN3	HSD11B1	P28845	507

IntAct

16 interactions, top by confidence:

A	B	Type	Score
FN1	FBN3	psi-mi:“MI:0407”(direct interaction)	0.440
FBN3	ANXA7	psi-mi:“MI:0915”(physical association)	0.370
FBN3	BID	psi-mi:“MI:0915”(physical association)	0.370
SMAP	FBN3	psi-mi:“MI:0915”(physical association)	0.370
FBN3	CDKN1A	psi-mi:“MI:0915”(physical association)	0.370
FBN3	DAZAP2	psi-mi:“MI:0915”(physical association)	0.370
FBN3	GADD45A	psi-mi:“MI:0915”(physical association)	0.370
GSK3B	FBN3	psi-mi:“MI:0915”(physical association)	0.370
NUDT21	FBN3	psi-mi:“MI:0915”(physical association)	0.370
FBN3	PIK3R3	psi-mi:“MI:0915”(physical association)	0.370
RPN2	FBN3	psi-mi:“MI:0915”(physical association)	0.370
RPS6KA6	FBN3	psi-mi:“MI:0915”(physical association)	0.370
FBN3	TK1	psi-mi:“MI:0915”(physical association)	0.370
TSC22D1	FBN3	psi-mi:“MI:0915”(physical association)	0.370
FBN3		psi-mi:“MI:0915”(physical association)	0.370

BioGRID (16): FBN3 (Affinity Capture-MS), FBN3 (Affinity Capture-MS), FBN3 (Cross-Linking-MS (XL-MS)), FBN3 (Two-hybrid), FBN3 (Two-hybrid), FBN3 (Two-hybrid), FBN3 (Two-hybrid), FBN3 (Two-hybrid), FBN3 (Two-hybrid), FBN3 (Two-hybrid), FBN3 (Two-hybrid), FBN3 (Two-hybrid), FBN3 (Two-hybrid), FBN3 (Two-hybrid), FBN3 (Two-hybrid)

ESM2 similar proteins: A0A0R4IKU3, A1A5Y0, A2ASQ1, A2VCU8, A6QR11, O42182, O55225, P01130, P01131, P01132, P01133, P07522, P20063, P25304, P31696, P35950, P35951, P35952, P97607, Q00968, Q14393, Q28832, Q501P1, Q53RD9, Q5R3Z7, Q61220, Q61592, Q62918, Q62919, Q63772, Q66PY1, Q6ZRI0, Q75N90, Q7T3Q2, Q7ZXL5, Q8AWW5, Q8CJ69, Q8IX30, Q8N8U9, Q8R4Y4

Diamond homologs: A0A1U9VX91, A2AJ76, O08999, O43897, O57382, O57460, O75095, P13497, P35556, P98063, P98070, P98133, Q00918, Q14766, Q61555, Q62381, Q75N90, Q7KVA1, Q8C088, Q8CG19, Q8JI28, Q9DER7, Q9TV36, A1A5Y0, A2VCU8, A4IGL7, A5A8Y8, A6QR11, B5DFC9, O88322, P07996, P10493, P14585, P35441, P35448, P82279, P98118, Q14112, Q20911, Q24025

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

1691 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	930
Likely benign	485
Benign	164

Top pathogenic / likely-pathogenic (0)

SpliceAI

9896 predictions. Top by Δscore:

Variant	Effect	Δscore
19:8068767:C:A	donor_gain	1.0000
19:8085502:A:AC	donor_gain	1.0000
19:8085503:C:CC	donor_gain	1.0000
19:8086195:CTCA:C	donor_loss	1.0000
19:8086196:TCACC:T	donor_loss	1.0000
19:8086197:CAC:C	donor_loss	1.0000
19:8086197:CACC:C	donor_loss	1.0000
19:8086198:ACCGT:A	donor_loss	1.0000
19:8086199:C:T	donor_loss	1.0000
19:8086325:TCTGA:T	acceptor_loss	1.0000
19:8086326:CTGAG:C	acceptor_loss	1.0000
19:8087209:CAT:C	acceptor_gain	1.0000
19:8087212:C:CC	acceptor_gain	1.0000
19:8087215:C:CT	acceptor_gain	1.0000
19:8087218:A:AC	acceptor_gain	1.0000
19:8087223:C:CT	acceptor_gain	1.0000
19:8089544:CCCA:C	donor_gain	1.0000
19:8089668:CGT:C	acceptor_gain	1.0000
19:8089671:C:CC	acceptor_gain	1.0000
19:8089957:CAG:C	acceptor_gain	1.0000
19:8089960:C:CC	acceptor_gain	1.0000
19:8091459:ACTT:A	donor_loss	1.0000
19:8091460:CTTA:C	donor_loss	1.0000
19:8091461:TTA:T	donor_loss	1.0000
19:8091461:TTAC:T	donor_loss	1.0000
19:8091462:TA:T	donor_loss	1.0000
19:8091463:A:AC	donor_gain	1.0000
19:8091463:A:C	donor_loss	1.0000
19:8091463:ACCAA:A	donor_loss	1.0000
19:8091464:C:CA	donor_loss	1.0000

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000010403 (19:8068176 G>A), RS1000077154 (19:8146435 G>A), RS1000105578 (19:8135209 C>A,G,T), RS1000108382 (19:8099237 A>G), RS1000127667 (19:8110587 C>A), RS1000158641 (19:8110318 C>G), RS1000227751 (19:8068048 G>A,C), RS1000278431 (19:8140396 G>A), RS1000319399 (19:8081196 C>T), RS1000332045 (19:8151119 G>A,C), RS1000357719 (19:8116124 G>A,C), RS1000436036 (19:8072837 G>C), RS1000447647 (19:8085645 G>C,T), RS1000464960 (19:8106023 C>G,T), RS1000502179 (19:8090938 G>T)

Disease associations

OMIM: gene MIM:608529 | disease phenotypes: MIM:277600, MIM:109730

GenCC curated gene-disease

Mondo (2): Weill-Marchesani syndrome (MONDO:0018096), aortic valve disease 1 (MONDO:0024523)

Orphanet (1): Weill-Marchesani syndrome (Orphanet:3449)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

11 associations (top):

Study	Trait	p-value
GCST004406_2	Neurocognitive impairment in HIV-1 infection (continuous)	4.000000e-07
GCST005650_173	Serum metabolite ratios in chronic kidney disease	3.000000e-13
GCST006916_9	Attention deficit hyperactivity disorder	2.000000e-06
GCST008758_77	Pre-treatment viral load in HIV-1 infection	2.000000e-19
GCST010002_147	Refractive error	4.000000e-16
GCST012020_52	Serum metabolite levels	9.000000e-27
GCST012020_531	Serum metabolite levels	3.000000e-11
GCST012020_532	Serum metabolite levels	2.000000e-18
GCST012020_533	Serum metabolite levels	3.000000e-12
GCST012251_3	Macular telangiectasia type 2	3.000000e-07
GCST012252_10	Macular telangiectasia type 2	3.000000e-08

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0007998	cognitive impairment measurement
EFO:0010125	viral load
EFO:1002009	macular telangiectasia type 2

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D056846	Weill-Marchesani Syndrome	C05.116.099.343.957; C11.270.921; C16.131.077.941; C16.320.290.842; C17.300.899

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

28 total (human), top 28 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	decreases expression, affects expression, affects cotreatment	5
bisphenol A	decreases expression, decreases methylation	2
Phenylmercuric Acetate	decreases expression, affects cotreatment	2
2,4,6-tribromophenol	decreases expression	1
methylmercuric chloride	decreases expression	1
decabromobiphenyl ether	decreases expression	1
tetrabromobisphenol A	decreases expression	1
perfluorooctanoic acid	affects cotreatment, decreases expression	1
benzo(e)pyrene	increases methylation	1
aflatoxin B2	affects methylation	1
perfluorooctane sulfonic acid	affects cotreatment, decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	decreases expression, affects cotreatment	1
perfluorohexanesulfonic acid	affects cotreatment, decreases expression	1
belinostat	decreases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
pentabrominated diphenyl ether 100	decreases expression	1
hexabrominated diphenyl ether 153	decreases expression	1
bisphenol S	decreases methylation	1
Vorinostat	decreases expression	1
Arsenic	decreases expression	1
Benzo(a)pyrene	affects methylation	1
Diazinon	increases methylation	1
Methapyrilene	increases methylation	1
Tobacco Smoke Pollution	decreases expression	1
Aflatoxin B1	affects methylation	1
Acrylamide	decreases expression	1
S-Nitrosoglutathione	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.